SCHEMBL12979067

SCHEMBL12979067

CCOC(=O)Cn1cc(-c2cnc3ccc(N(S)C(=O)NCC4CC4)nc3n2)cn1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 12/20 0.41
▸ FGFR2 P21802 7/20 0.41
▸ FGFR4 P22455 7/20 0.41
▸ FGFR3 P22607 7/20 0.41
▸ KDR P35968 7/20 0.41
▸ JAK1 P23458 5/20 0.41
▸ JAK2 O60674 3/20 0.41
▸ TYK2 P29597 3/20 0.41
▸ JAK3 P52333 2/20 0.41
▸ MAPK1 P28482 2/20 0.41
▸ PIK3CA P42336 1/20 0.41
▸ MAPK8 P45983 1/20 0.41
▸ MAPK9 P45984 1/20 0.41
▸ MAPK10 P53779 1/20 0.41
▸ FLT3 P36888 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ HDAC1 Q13547 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12979282 0.91 MAPK1 (0.47) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL12979018 0.89 FGFR1 (0.40) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL12978714 0.88 FGFR1 (0.39) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL12979555 0.87 MAPK1 (0.45) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL12979617 0.87 MAPK1 (0.40) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL12979128 0.83 MAPK1 (0.40) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL12979271 0.83 MAPK1 (0.59) MAPK1PIK3CAMAPK8MAPK9MAPK10
SCHEMBL12979063 0.82 MAPK1 (0.51) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL12979519 0.82 ACACB (0.48) FGFR1FGFR2FGFR4FGFR3KDR
SCHEMBL12978948 0.79 DYRK1A (0.41) MAPK1PIK3CAMAPK8MAPK9MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2694068-A1 PYRIDOPYRAZINE DERIVATIVES AND THEIR USE Æterna Zentaris GmbH (DE) 2014-02-12 — — EP claimed
US-20120259151-A1 PYRIDOPYRAZINE DERIVATIVES AND THEIR USE AETERNA ZENTARIS GMBH (DE) 2012-10-11 — — US claimed
WO-2012136694-A1 PYRIDOPYRAZINE DERIVATIVES AND THEIR USE ÆTERNA ZENTARIS GMBH (DE) 2012-10-11 — — WO claimed
US-8912189-B2 Pyridopyrazine derivatives and their use AETERNA ZENTARIS GMBH (DE) 2014-12-16 — — US disclosed
US-20120259151-A1 PYRIDOPYRAZINE DERIVATIVES AND THEIR USE AETERNA ZENTARIS GMBH (DE) 2012-10-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120259151-A1 PYRIDOPYRAZINE DERIVATIVES AND THEIR USE PLPBP, PDXK, MAP4K2 FGFR1 1814/4885FGFR2 2897/4885FGFR4 2389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback